Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Nirav N. Shah et al.|The Lancet|2021Cited by 456
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, John F. Seymour et al.|New England Journal of Medicine|2023Cited by 213
Real-world experience with caplacizumab in the management of acute TTPTina Dutt, Marie Scully, Rebecca Shaw et al.|Blood|2020Cited by 157
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, David A. Cairns et al.|New England Journal of Medicine|2023Cited by 155
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A. Eyre, Graham P. Collins, Harriet S. Walter et al.|Haematologica|2018Cited by 137